These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32411592)

  • 1. Pharmacogenomic Testing to Guide Personalized Cancer Medicine Decisions in Private Oncology Practice: A Case Study.
    Astras G; Papagiannopoulos CI; Kyritsis KA; Markitani C; Vizirianakis IS
    Front Oncol; 2020; 10():521. PubMed ID: 32411592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
    Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
    Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Genomic Practice in Oncology: Pharmacist Role and Experience in an Ambulatory Care Clinic.
    Raheem F; Kim P; Grove M; Kiel PJ
    Pharmacy (Basel); 2020 Mar; 8(1):. PubMed ID: 32182657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.
    Dalton WB; Forde PM; Kang H; Connolly RM; Stearns V; Gocke CD; Eshleman JR; Axilbund J; Petry D; Geoghegan C; Wolff AC; Loeb DM; Pratilas CA; Meyer CF; Christenson ES; Slater SA; Ensminger J; Parsons HA; Park BH; Lauring J
    JCO Precis Oncol; 2017; 2017():. PubMed ID: 30003184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice.
    Martens UM; Schröder J; Bengsch F; Sellmann L; Busies S; Frank-Gleich S; Zaiss M; Decker T; Schneeweiss A; Schuler M; Grebhardt S; Zacharias S; Marschner N; Kasenda B; Potthoff K; Vannier C
    BMC Cancer; 2023 Jun; 23(1):543. PubMed ID: 37312086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision oncology using a clinician-directed, tailored approach to molecular profiling.
    Lam M; Tran B; Beck S; Tie J; Herath D; Whittle J; Kwan EM; Fox SB; Fellowes A; Ananda S; Lipton L; Gibbs P; Rosenthal MA; Desai J
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):84-90. PubMed ID: 29083093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy.
    Khotskaya YB; Mills GB; Mills Shaw KR
    Annu Rev Med; 2017 Jan; 68():113-125. PubMed ID: 27813876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.
    Lauschke VM; Milani L; Ingelman-Sundberg M
    AAPS J; 2017 Nov; 20(1):4. PubMed ID: 29181807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision oncology based on omics data: The NCT Heidelberg experience.
    Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
    Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review).
    Christofyllakis K; Bittenbring JT; Thurner L; Ahlgrimm M; Stilgenbauer S; Bewarder M; Kaddu-Mulindwa D
    Mol Clin Oncol; 2022 Jan; 16(1):21. PubMed ID: 34909199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation and utilization of the molecular tumor board to guide precision medicine.
    Harada S; Arend R; Dai Q; Levesque JA; Winokur TS; Guo R; Heslin MJ; Nabell L; Nabors LB; Limdi NA; Roth KA; Partridge EE; Siegal GP; Yang ES
    Oncotarget; 2017 Aug; 8(34):57845-57854. PubMed ID: 28915716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
    Dy GK; Nesline MK; Papanicolau-Sengos A; DePietro P; LeVea CM; Early A; Chen H; Grand'Maison A; Boland P; Ernstoff MS; Edge S; Akers S; Opyrchal M; Chatta G; Odunsi K; Pabla S; Conroy JM; Glenn ST; DeFedericis HT; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Kanehira K; Lenzo FL; Frederick P; Lele S; Galluzzi L; Kuvshinoff B; Morrison C
    BMC Med Inform Decis Mak; 2019 Jan; 19(1):14. PubMed ID: 30658646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine for metastatic colorectal cancer: an evolving era.
    Guler I; Askan G; Klostergaard J; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
    [No Abstract]   [Full Text] [Related]  

  • 16. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
    Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
    Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supporting the decision to perform molecular profiling for cancer patients based on routinely collected data through the use of machine learning.
    Kasprzak J; Westphalen CB; Frey S; Schmitt Y; Heinemann V; Fey T; Nasseh D
    Clin Exp Med; 2024 Apr; 24(1):73. PubMed ID: 38598013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials for precision oncology using next-generation sequencing.
    Simon R; Polley E
    Per Med; 2013 Jul; 10(5):485-495. PubMed ID: 29758837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical impact of using complex molecular profiling strategies in routine oncology practice.
    Laes JF; Aftimos P; Barthelemy P; Bellmunt J; Berchem G; Camps C; Peñas RL; Finzel A; García-Foncillas J; Hervonen P; Wahid I; Joensuu T; Kathan L; Kong A; Mackay J; Mikropoulos C; Mokbel K; Mouysset JL; Odarchenko S; Perren TJ; Pienaar R; Regonesi C; Alkhayyat SS; El Kinge AR; Abulkhair O; Galal KM; Ghanem H; El Karak F; Garcia A; Ghitti G; Sadik H
    Oncotarget; 2018 Apr; 9(29):20282-20293. PubMed ID: 29755651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.